# Ionis Clinical Trial Transparency Statement

## Introduction

At Ionis, we are committed to sharing data from our clinical research and clinical trials in a transparent and responsible manner.

We support data transparency that furthers science and drug discovery, protects participant confidentiality and privacy, and is in the best interest of individuals who use our medicines and the providers who prescribe them.

Our pipeline of investigational medicines can be found at: https://www.ionispharma.com/ionis-technology/antisense-pipeline/.

Our Clinical Trial Transparency commitment outlines the framework we follow in sharing clinical trial information with trial participants, family members and other caregivers, physicians, regulators, and independent researchers. We will continue to review and update this commitment where appropriate as transparency regulations change and needs for open data sharing evolve.

## Transparency Activities at Ionis

### Clinical Trial Registration

Ionis registers protocol information for company sponsored clinical trials of investigational and marketed products on clinical trial registries such as ClinicalTrials.gov, the European Union Clinical Trials Register (EU CTR) and the European Union (EU) Clinical Trials Information System (CTIS). Studies are registered in compliance with applicable laws and regulations.

### Clinical Trial Result Summaries

Ionis discloses the results of company sponsored clinical trials in accordance with applicable laws and regulations. Summary results (e.g., technical and Plain Language Summaries, when required) of Ionis-sponsored trials are reported on registries such as ClinicalTrials.gov and/or the EU CTR or CTIS.

In accordance with applicable laws and regulations, Ionis is committed to providing trial summaries in an easy-to-understand format, known as plain language summaries, to trial participants, regulatory agencies, and the public.

**Publication of Clinical Trial Results**

Ionis is committed to sharing the findings of our research and clinical trial results in a transparent, ethical, and accurate manner. Ionis is committed to submitting the results of company sponsored clinical trials, for publication in peer-reviewed journals or at scientific meetings, to further science and move closer to improving the lives of patients.

**Clinical Trial Data Sharing**

Ionis' commitment to transparency includes establishing a mechanism for sharing anonymized individual participant data, aggregated clinical data, and other types of data with qualified scientific and medical researchers. Ionis has joined the Vivli consortium, an independent, nonprofit organization that has developed a global data-sharing and analytics platform.

Qualified researchers can make data requests through Vivli.org. Requests will be considered based on select evaluation criteria including: the request is 12 months from marketing approval of the study drug in both the United States and European Union; 18 months from conclusion of the study; and six months from publication of study results. Requests are contingent upon approval of a research proposal and entry into an appropriate data use agreement.

For more information on our data-sharing scope and policy, visit the Vivli website at: https://vivli.org/ourmember/ionis/.